EYPT
Price
$8.04
Change
+$0.32 (+4.14%)
Updated
Jan 30, 04:59 PM (EDT)
Capitalization
527.58M
27 days until earnings call
MNMD
Price
$7.12
Change
-$0.20 (-2.73%)
Updated
Jan 30, 04:59 PM (EDT)
Capitalization
536.79M
26 days until earnings call
Ad is loading...

EYPT vs MNMD

Header iconEYPT vs MNMD Comparison
Open Charts EYPT vs MNMDBanner chart's image
EyePoint Pharmaceuticals
Price$8.04
Change+$0.32 (+4.14%)
Volume$10.16K
Capitalization527.58M
Mind Medicine (MindMed)
Price$7.12
Change-$0.20 (-2.73%)
Volume$3.64K
Capitalization536.79M
EYPT vs MNMD Comparison Chart
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. MNMD commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Buy and MNMD is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (EYPT: $8.05 vs. MNMD: $7.13)
Brand notoriety: EYPT and MNMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 66% vs. MNMD: 87%
Market capitalization -- EYPT: $527.58M vs. MNMD: $536.79M
EYPT [@Biotechnology] is valued at $527.58M. MNMD’s [@Biotechnology] market capitalization is $536.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileMNMD’s FA Score has 1 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • MNMD’s FA Score: 1 green, 4 red.
According to our system of comparison, MNMD is a better buy in the long-term than EYPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 3 TA indicator(s) are bullish while MNMD’s TA Score has 4 bullish TA indicator(s).

  • EYPT’s TA Score: 3 bullish, 5 bearish.
  • MNMD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MNMD is a better buy in the short-term than EYPT.

Price Growth

EYPT (@Biotechnology) experienced а -8.73% price change this week, while MNMD (@Biotechnology) price change was -0.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.11%. For the same industry, the average monthly price growth was +1.05%, and the average quarterly price growth was +4.49%.

Reported Earning Dates

EYPT is expected to report earnings on May 07, 2025.

MNMD is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (-1.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNMD($537M) and EYPT($528M) have the same market capitalization . EYPT YTD gains are higher at: 8.054 vs. MNMD (2.443). MNMD has higher annual earnings (EBITDA): -93.47M vs. EYPT (-102.3M). MNMD has more cash in the bank: 295M vs. EYPT (254M). EYPT has less debt than MNMD: EYPT (21.9M) vs MNMD (24.3M). EYPT has higher revenues than MNMD: EYPT (45.7M) vs MNMD (0).
EYPTMNMDEYPT / MNMD
Capitalization528M537M98%
EBITDA-102.3M-93.47M109%
Gain YTD8.0542.443330%
P/E RatioN/AN/A-
Revenue45.7M0-
Total Cash254M295M86%
Total Debt21.9M24.3M90%
FUNDAMENTALS RATINGS
EYPT vs MNMD: Fundamental Ratings
EYPT
MNMD
OUTLOOK RATING
1..100
1162
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
31
Undervalued
PROFIT vs RISK RATING
1..100
10084
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6441
P/E GROWTH RATING
1..100
20100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (31) in the null industry is in the same range as EYPT (63) in the Pharmaceuticals Major industry. This means that MNMD’s stock grew similarly to EYPT’s over the last 12 months.

MNMD's Profit vs Risk Rating (84) in the null industry is in the same range as EYPT (100) in the Pharmaceuticals Major industry. This means that MNMD’s stock grew similarly to EYPT’s over the last 12 months.

MNMD's SMR Rating (97) in the null industry is in the same range as EYPT (98) in the Pharmaceuticals Major industry. This means that MNMD’s stock grew similarly to EYPT’s over the last 12 months.

MNMD's Price Growth Rating (41) in the null industry is in the same range as EYPT (64) in the Pharmaceuticals Major industry. This means that MNMD’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for MNMD (100) in the null industry. This means that EYPT’s stock grew significantly faster than MNMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTMNMD
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 25 days ago
82%
Bullish Trend 25 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LAFAX26.680.39
+1.48%
Columbia Acorn International Sel A
EQNUX21.980.10
+0.46%
MFS Equity Income R4
CIRRX17.20N/A
N/A
Cohen & Steers Real Estate Securities R
JAVAX14.60N/A
N/A
James Aggressive Allocation
GSMAX21.98N/A
N/A
Goldman Sachs Small/Mid Cap Growth A

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+4.14%
LYRA - EYPT
59%
Loosely correlated
+0.44%
ATHE - EYPT
54%
Loosely correlated
+57.04%
GLYC - EYPT
46%
Loosely correlated
+13.86%
OCUL - EYPT
44%
Loosely correlated
-0.77%
BEAM - EYPT
39%
Loosely correlated
+5.29%
More

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with LABFF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then LABFF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
-2.60%
LABFF - MNMD
47%
Loosely correlated
N/A
IMRN - MNMD
45%
Loosely correlated
+7.46%
ATAI - MNMD
45%
Loosely correlated
+6.67%
VCYT - MNMD
40%
Loosely correlated
+3.83%
RAPT - MNMD
36%
Loosely correlated
-2.56%
More